Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer

E. T. Creagan, J. R. O'Fallon, J. E. Woods, J. N. Ingle, A. J. Schutt, W. C. Nichols

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A regression rate of 12% (4/33) among patients with advanced upper aerodigestive carcinomas who received an intravenous regimen of cis-diamminedichloroplatinum, 90 mg/m2/24 hours each 3 weeks was achieved. The response rate was 13% (3/23) among patients with typical squamous cell carcinoma. Most individuals had received extensive prior surgery and/or radiation therapy. Nineteen patients had ECOG performance score 0, 1. A median time to progression and survival of 1.6 months and 6.7 months, respectively, were associated with moderate to severe nausea and vomiting in virtually all patients. These results differ from previous reports of single agent platinum regimens which have achieved regression rates of approximately 40% among apparently comparable patients. Subtle clinically inapparent differences between study populations and the influence of yet unrecognized covariates may have impacted on the response discrepancy. Innovative studies of the high-dose, infusion platinum therapy may clarify the efficacy of the program in patients with advanced head and neck cancer.

Original languageEnglish (US)
Pages (from-to)2020-2023
Number of pages4
JournalCancer
Volume51
Issue number11
StatePublished - 1983

Fingerprint

Cisplatin
Neoplasms
Platinum
Therapeutics
Head and Neck Neoplasms
Nausea
Vomiting
Squamous Cell Carcinoma
Radiotherapy
Carcinoma
Survival
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Creagan, E. T., O'Fallon, J. R., Woods, J. E., Ingle, J. N., Schutt, A. J., & Nichols, W. C. (1983). Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer. Cancer, 51(11), 2020-2023.

Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer. / Creagan, E. T.; O'Fallon, J. R.; Woods, J. E.; Ingle, J. N.; Schutt, A. J.; Nichols, W. C.

In: Cancer, Vol. 51, No. 11, 1983, p. 2020-2023.

Research output: Contribution to journalArticle

Creagan, ET, O'Fallon, JR, Woods, JE, Ingle, JN, Schutt, AJ & Nichols, WC 1983, 'Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer', Cancer, vol. 51, no. 11, pp. 2020-2023.
Creagan, E. T. ; O'Fallon, J. R. ; Woods, J. E. ; Ingle, J. N. ; Schutt, A. J. ; Nichols, W. C. / Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer. In: Cancer. 1983 ; Vol. 51, No. 11. pp. 2020-2023.
@article{11a1716e07f042d88582d500c9fa875c,
title = "Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer",
abstract = "A regression rate of 12{\%} (4/33) among patients with advanced upper aerodigestive carcinomas who received an intravenous regimen of cis-diamminedichloroplatinum, 90 mg/m2/24 hours each 3 weeks was achieved. The response rate was 13{\%} (3/23) among patients with typical squamous cell carcinoma. Most individuals had received extensive prior surgery and/or radiation therapy. Nineteen patients had ECOG performance score 0, 1. A median time to progression and survival of 1.6 months and 6.7 months, respectively, were associated with moderate to severe nausea and vomiting in virtually all patients. These results differ from previous reports of single agent platinum regimens which have achieved regression rates of approximately 40{\%} among apparently comparable patients. Subtle clinically inapparent differences between study populations and the influence of yet unrecognized covariates may have impacted on the response discrepancy. Innovative studies of the high-dose, infusion platinum therapy may clarify the efficacy of the program in patients with advanced head and neck cancer.",
author = "Creagan, {E. T.} and O'Fallon, {J. R.} and Woods, {J. E.} and Ingle, {J. N.} and Schutt, {A. J.} and Nichols, {W. C.}",
year = "1983",
language = "English (US)",
volume = "51",
pages = "2020--2023",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Cis-diamminedichloroplatinum (II) administered by 24-hour infusion in the treatment of patients with advanced upper aerodigestive cancer

AU - Creagan, E. T.

AU - O'Fallon, J. R.

AU - Woods, J. E.

AU - Ingle, J. N.

AU - Schutt, A. J.

AU - Nichols, W. C.

PY - 1983

Y1 - 1983

N2 - A regression rate of 12% (4/33) among patients with advanced upper aerodigestive carcinomas who received an intravenous regimen of cis-diamminedichloroplatinum, 90 mg/m2/24 hours each 3 weeks was achieved. The response rate was 13% (3/23) among patients with typical squamous cell carcinoma. Most individuals had received extensive prior surgery and/or radiation therapy. Nineteen patients had ECOG performance score 0, 1. A median time to progression and survival of 1.6 months and 6.7 months, respectively, were associated with moderate to severe nausea and vomiting in virtually all patients. These results differ from previous reports of single agent platinum regimens which have achieved regression rates of approximately 40% among apparently comparable patients. Subtle clinically inapparent differences between study populations and the influence of yet unrecognized covariates may have impacted on the response discrepancy. Innovative studies of the high-dose, infusion platinum therapy may clarify the efficacy of the program in patients with advanced head and neck cancer.

AB - A regression rate of 12% (4/33) among patients with advanced upper aerodigestive carcinomas who received an intravenous regimen of cis-diamminedichloroplatinum, 90 mg/m2/24 hours each 3 weeks was achieved. The response rate was 13% (3/23) among patients with typical squamous cell carcinoma. Most individuals had received extensive prior surgery and/or radiation therapy. Nineteen patients had ECOG performance score 0, 1. A median time to progression and survival of 1.6 months and 6.7 months, respectively, were associated with moderate to severe nausea and vomiting in virtually all patients. These results differ from previous reports of single agent platinum regimens which have achieved regression rates of approximately 40% among apparently comparable patients. Subtle clinically inapparent differences between study populations and the influence of yet unrecognized covariates may have impacted on the response discrepancy. Innovative studies of the high-dose, infusion platinum therapy may clarify the efficacy of the program in patients with advanced head and neck cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020638890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020638890&partnerID=8YFLogxK

M3 - Article

C2 - 6682349

AN - SCOPUS:0020638890

VL - 51

SP - 2020

EP - 2023

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -